Navigation Links
Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Date:9/8/2008

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it received a milestone payment for an undisclosed amount from its licensing partner, Pfizer Inc. (NYSE: PFE). This payment is a result of the submission of an Investigational New Drug (IND) application by Pfizer for the clinical development of an antibody generated by Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

"We are pleased with the progress that Pfizer has made in advancing this antibody, generated using our UltiMAb(R) technology, towards the clinic," said Howard H. Pien, President and CEO of Medarex. "The continued development progress by Pfizer and our other partners reinforces the potential of products generated using our UltiMAb(R) antibody technology to treat life-threatening diseases."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
2. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
5. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
6. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Medarex Announces Ipilimumab Program Continues to Move Forward
9. Medarex to Receive Milestone Payment from Amgen
10. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
11. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,
(Date:12/4/2009)SALT LAKE CITY, Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) announced it has signed a sole-source vendor agreement to provide therapy equipment and rehab supplies to Benchmark Physical Therapy wi
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Worries May Worsen Peripheral Arterial Disease 54672 1Worries May Worsen Peripheral Arterial Disease 54672 2Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 1Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 2Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 1Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 2Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 3
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3
...e smoking there is probably misuse of alcohol too,...esearchers in the Archives// of Internal Medicine.... used as a clinical indicator for alcohol misuse, ... although brief screening and brief intervention p...
...umer interests and those of the pharmaceutical ind... Senate Committee approved// a bill that would clo...cessary powers to require drug makers to wait two ...il to do post-approval studies and to ban advertis...
...he flu is nothing to be sneezed at//. The res...iversity of Texas-Houston, showed that about 90, 0...he U.S alone. The researchers say that this i... heart disease should never forgo their medication...
...h Haikerwal, said today that war veterans would ha...vices from 1 May following// the introduction of i... Officer (LMO) scheme for veterans’ health care. ... In practical terms, this means that patients ...
...ted that only a small percentage of food imported ...her, the 1.3% that is inspected// reveal contamina...he rest of the food that escapes inspection? ...to lenient food laws in the countries from where t...
...argest collections of liver tissue samples ever ac...System researchers have embarked on a massive stud... Nonalcoholic fatty liver disease starts with t...potentially fatal cirrhosis. If the damage becomes...
Other Medicine News:Health News:Smoking Indicator of Alcohol Misuse 2Health News:Moratorium Proposed on Advertisements of Newly Approved Drugs 2Health News:The Flu- More Than Just That 2Health News:Geisinger Launches Extensive Study on Obesity and Related Liver Problem 2
Insulin Autoantibody (IAA)
Benchtop Laminar Hood (Universal Hood)
Remote Blower With Bag-In/Bag-Out Option
Class II Type B2 Biological Safety Cabinet
Medicine Products: